PD-019RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & amp; combination with Phase I and IIa data including imaging and lab profiles [U.S.FDA BB-IND 10091]

We report ongoing human experience using mouse renal adenocarcinoma cells (RENCA) entrapped in agarose macrobeads (RMB) for late-stage mCRC therapy (Chin J Cancer Res 2018;30(1):72-83). Such cells undergo genomic changes that release multiple anti-neoplastic factors (> ten). One or more achieve 40% of their tumor-cell inhibitory effect via MEF-2 regulation. (Cancer Res. 2011;71(3): 716 –724;725–735). Other pathways are currently under study with Lund University. Phase I and IIa RMB trials provided evidence of survival and quality of life benefit in treatment-resistant, late-stage mCRC patients (Cancer Growth Metastasis.2016;9:9–20). Here, we report the combined findings of t he P I/IIa, along with new preliminary survival and other-benefit findings from a PIIb multi-site trial.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research